Nasdaq Approves Jupiter Neurosciences' Listing Due to Meeting Share Price Requirement

Jupiter Neurosciences (JUNS) has met Nasdaq's share price requirement, adhering to Rule 5550 of the listing qualifications. The company's compliance with the necessary stock price standards allows it to continue its listing on the exchange.

Jupiter Neurosciences (JUNS), a clinical-stage pharmaceutical company, has successfully regained compliance with Nasdaq's minimum share price requirement, adhering to Rule 5550 of the listing qualifications. The company's stock maintained an average closing price of at least $1.00 for 13 consecutive trading days from June 18 to July 8, 2025 [1].

The compliance confirmation was received on July 9, 2025, from Nasdaq's Listing Qualifications Department. This resolution effectively addresses the previous listing concern, allowing Jupiter's shares to fully comply with Rule 5550(a)(2) and close the matter [1]. The positive upward trend in Jupiter's stock price has contributed to this achievement [2].

Jupiter Neurosciences is focused on addressing neuroinflammation and promoting healthy aging. The company's therapeutic pipeline targets central nervous system (CNS) disorders and rare diseases, while its consumer longevity market, Nugevia™, brings clinical-grade science to the supplement space [1]. The company's proprietary, enhanced resveratrol formulation, JOTROL™, powers both efforts, demonstrating significantly improved bioavailability [1].

The company's continued listing on the Nasdaq Stock Market is now secure, following this positive development. Investors are encouraged to review the risk factors and forward-looking statements in Jupiter's filings for a comprehensive understanding of the company's potential future performance [1].

References:
[1] https://www.stocktitan.net/news/JUNS/jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-ag2hxh9iqoj5.html
[2] https://www.nasdaq.com/press-release/jupiter-neurosciences-regains-compliance-nasdaq-minimum-bid-price-requirement-2025-07